Correction: Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity

Correction to: Oncogene 10.1038/s41388-021-02039-2, published online 28 October 2021

In the original version, details about the animal ethics approval were not mentioned in the section ‘Assessment of in vivo tumor growth’. Accordingly the text passage now reads as follows:

‘P. Rocchi who supervised the animal experiments, obtained permission for animal experiments by ethical committee following European rules (APAFIS#26169-2020062314545490 v4, Direction générale de la recherche et de l’innovation (DGRI), 75231 Paris Cedex 05)’ instead of ‘Palma Rocchi possesses personal agreement (#A13-477) for the animal handling and experimentation for this study. Animal experimentation was carried out accordingly to ethics laws recommendations’.

Correction to: Competing Interests

In the original version, the ‘Competing Interest’ statement was incorrectly given as ‘The authors declare no competing interests’ but should have been ‘The University of British Columbia has submitted patent applications on Apatorsen, an antisense inhibitor of Hsp27, listing PR and MG as inventors. This IP has been licensed to OncoGenex Technologies, a Vancouver-based biotechnology company. PR and DT are cofounders of SilonTx ([Silon Therapeutics | Advancing Innovative Therapies | https://silontx.com/]), a biotech company started in April 2024 focusing on precision medicine and nucleic acid therapeutics’.

The original article has been corrected.